Koyfin Home > Directory > Health Care > Adverum Biotechnlgs > Repurchase of Common Stock

Adverum Biotechnlgs Repurchase of Common Stock Chart (ADVM)

Adverum Biotechnlgs annual/quarterly Repurchase of Common Stock from 2014 to 2020.
  • Adverum Biotechnlgs Repurchase of Common Stock for the quarter ending June 06, 2020 was $0m a -71.07% increase of 0m year over year
  • Adverum Biotechnlgs Repurchase of Common Stock for the last 12 months ending June 06, 2020 was $-2m a 32.22% decrease of -1m year over year
  • Adverum Biotechnlgs Annual Repurchase of Common Stock for 2019 was $-1m a 18.98% decrease of 0m from 2018
  • Adverum Biotechnlgs Annual Repurchase of Common Stock for 2018 was $-1m a 73.72% decrease of -1m from 2017
  • Adverum Biotechnlgs Annual Repurchase of Common Stock for 2017 was $0m a -57.51% increase of 0m from 2016
Other Cash Flow Metrics:
  • Adverum Biotechnlgs Cash Flow from Operations for the quarter ending December 12, 2018 was $-13m a -2.00% increase of 0m year over year
  • Adverum Biotechnlgs Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-26m a 70.14% decrease of -18m year over year
  • Adverum Biotechnlgs Total Revenue for the quarter ending September 09, 2018 was $1m a 44.66% increase of 0m year over year
View Chart On Koyfin

Quarterly ADVM Repurchase of Common Stock Data

06/2020$0m
03/2020$-2m
12/2019$0m
09/2019$0m
06/2019$-1m
03/2019$-1m
12/2018$0m
09/2018$0m
06/2018$0m
03/2018$-1m

Annual ADVM Repurchase of Common Stock Data

2019$-1m
2018$-1m
2017$0m
2016$0m
2015$0m